Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

MAIT and other innate-like T cells integrate adaptive immune responses to modulate interval-dependent reactogenicity to mRNA vaccines.

Amini A. et al, (2025), Sci Immunol, 10

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).

Li G. et al, (2025), Vaccine, 62

Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.

Janani L. et al, (2025), J Infect

WHO preferred product characteristics for bivalent Salmonella Typhi/Paratyphi A vaccine for comprehensive protection against enteric fever– key considerations and research gaps

Ibarz Pavon AB. et al, (2025)

Bivalent prefusion F vaccination in pregnancy and respiratory syncytial virus hospitalisation in infants in the UK: results of a multicentre, test-negative, case-control study.

Williams TC. et al, (2025), Lancet Child Adolesc Health

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Dold C. et al, (2025), Science Translational Medicine, 17

The validity of test-negative design for assessment of typhoid conjugate vaccine protection: comparison of estimates by different study designs using data from a cluster-randomised controlled trial.

Feng S. et al, (2025), Lancet Glob Health

The effect of pertussis vaccination in pregnancy on the immunogenicity of acellular or whole-cell pertussis vaccination in Gambian infants (GaPS): a single-centre, randomised, controlled, double-blind, phase 4 trial.

Saso A. et al, (2025), Lancet Infect Dis

Maternal views on RSV vaccination during the first season of implementation in England and Scotland.

Williams TC. et al, (2025), Lancet Infect Dis, 25, e135 - e136

Evaluation of naturally occurring IgG anti-Vi antibody titers as predictors and correlates of typhoid fever in Dhaka, Bangladesh.

Khanam F. et al, (2025), BMC Infect Dis, 25

Past, present, and future of Phase 3 vaccine trial design: rethinking statistics for the 21st century.

Janani L. et al, (2025), Clin Exp Immunol, 219

Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST).

Marchese AM. et al, (2025), Vaccine, 44

Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled study protocol.

Brito-Mutunayagam S. et al, (2025), PLoS One, 20

5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.

Qadri F. et al, (2024), Lancet, 404, 1419 - 1429

Spatial and temporal clustering of typhoid fever in an urban slum of Dhaka City: Implications for targeted typhoid vaccination.

Ahmmed F. et al, (2024), PLoS Negl Trop Dis, 18

The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.

Maytum A. et al, (2024), Pediatr Infect Dis J

Paediatric meningitis in the conjugate vaccine era and a novel clinical decision model to predict bacterial aetiology.

Martin NG. et al, (2024), J Infect, 88

Evaluating the Impact of the BioFire FilmArray in Childhood Meningitis: An Observational Cohort Study.

Kadambari S. et al, (2024), Pediatr Infect Dis J, 43, 345 - 349

Intravenous immunoglobulin treatment for encephalitis in children aged 6 months to 16 years: the IgNiTE RCT

Iro MA. et al, (2024), Efficacy and Mechanism Evaluation, 1 - 53

Protocol for the challenge non-typhoidal Salmonella (CHANTS) study: a first-in-human, in-patient, double-blind, randomised, safety and dose-escalation controlled human infection model in the UK.

Smith C. et al, (2024), BMJ Open, 14

Load More